Study Finds Underdiagnosis of Mild Cognitive Impairment in Older Adults and Highlights Need for Increased Awareness
New research conducted by scientists at the USC Dornsife College of Letters, Arts and Sciences has revealed alarming rates of underdiagnosis of mild cognitive impairment (MCI) among older adults, potentially hindering early intervention and treatment for Alzheimer’s disease.
Mild cognitive impairment is often considered an early sign of Alzheimer’s disease, yet many individuals with MCI are oblivious to their condition. The two studies conducted by USC researchers shed light on the prevalence of underdiagnosis and its detrimental impact on individuals’ access to preventive measures and innovative therapies.
In one study, researchers discovered that Medicare beneficiaries aged 65 and older had a diagnosis rate of less than 8% for MCI, indicating a vast majority of cases going undetected. This underdiagnosis prevents affected individuals from receiving the care needed to slow down the progression of Alzheimer’s disease.
Socioeconomic and clinical factors, including cardiovascular disease and diabetes, were found to increase the risk of cognitive decline and dementia, particularly in historically disadvantaged groups. Alarmingly, detection rates for MCI were even lower in these vulnerable populations, significantly increasing the burden of the disease while limiting their access to diagnosis and treatment.
Another study revealed that a staggering 99% of primary care clinicians underdiagnosed MCI, emphasizing the critical need for improved detection methods and greater physician awareness. MCI is different from dementia, as it doesn’t cause disability but presents sporadic challenges in day-to-day functioning.
MCI can manifest in various forms, such as forgetfulness, executive dysfunction, and mild changes in personality. Early detection is crucial, as recent advancements in Alzheimer’s disease treatment have the highest therapeutic potential when implemented at an early stage.
The underdiagnosis of MCI can be attributed to various factors, including individuals not expressing concerns, physicians missing subtle signs, and insufficient time during clinical visits. To address this issue, implementing risk-based MCI detection and utilizing digital tests prior to medical visits could help identify more cases and raise awareness of cognitive risk.
Prompt treatment is vital, as the brain’s ability to recover from MCI is limited, and the damage caused cannot be reversed. The studies underscore the importance of increasing awareness about MCI, differentiating it from normal aging, and providing access to early detection and treatment options.
These findings call for immediate action to improve the diagnosis rates of MCI, particularly in vulnerable populations, and ensure that individuals receive the necessary care and treatment to manage cognitive decline effectively.
– Mattke, Soeren et al. “Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis.” Alzheimer’s Research & Therapy (2023).
– “Detection Rates of Mild Cognitive Impairment in Primary Care for the United States Medicare Population.” The Journal of Prevention of Alzheimer’s Disease (2023).
“Social media scholar. Reader. Zombieaholic. Hardcore music maven. Web fanatic. Coffee practitioner. Explorer.”